Olmesartan Vir (Olmesartan Medoxomil)

Olmesartan medoxomil selectively blocks the AT1 subtype of angiotensin II receptors. This inhibition prevents angiotensin II‑induced vasoconstriction and aldosterone release, leading to relaxed blood vessels, reduced sodium and water retention, and a subsequent fall in systemic blood pressure.

The appropriate dose of Olmesartan Vir is determined by a qualified prescriber based on the individual’s blood pressure, response to therapy, and clinical condition. Dosage adjustments are made according to therapeutic goals and tolerability.

Olmesartan Vir is classified as Pregnancy Category D, indicating evidence of fetal risk and it should be avoided in pregnancy. Safety during breastfeeding has not been established, so the drug is generally not recommended for nursing mothers unless the benefit outweighs the risk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Olmesartan Vir belongs to the ARB class, which offers blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough and angioedema. Compared with calcium‑channel blockers, ARBs act on the renin‑angiotensin system rather than directly relaxing vascular smooth muscle.

Olmesartan Vir should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Olmesartan Vir is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious risks include angioedema, which can cause swelling of the face, lips, tongue, or throat, and hyperkalaemia, a potentially dangerous rise in blood potassium levels. Acute kidney injury may also occur, especially when combined with other nephrotoxic agents.

Olmesartan Vir should not be used by individuals with known hypersensitivity to olmesartan or any component of the formulation, pregnant women, or patients with severe hepatic impairment. Caution is also advised for those with bilateral renal artery stenosis or significant renal dysfunction.